The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
354a
ONGOING PHASE 1B/2 TRIAL OF THE ALLOSTERIC MEK1/2 INHIBITOR REC-4881 AS MONOTHERAPY IN FAMILIAL ADENOMATOUS POLYPOSIS (FAP): PRELIMINARY SAFETY AND EFFICACY DATA
Date
May 4, 2025
Explore related products in the following collection:
